Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Asia Green Biotechnology Corp., an early stage international bio-technology company, focuses on the development, evaluation, testing, application, and supply of products derived from proprietary organic hybridization technology in Asia. The company focuses on planting, growing, and harvesting new and valuable strains of hemp and related crops. It has an agreement with Pathway Rx Inc. and PNW Biosciences Inc. for the clinical development and commercialization of the cannabis sativa varieties for prevention and treatment of COVID-19 and other infectious diseases. The company was formerly known as Asia Cannabis Corp. and changed its name to Asia Green Biotechnology Corp. in April 2020. Asia Green Biotechnology Corp. was incorporated in 2017 and is based in Calgary, Canada.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. In particular, the stock is 'expensive' on EV/EBITDA.
Buy
Sell